Pruijm Menno T, Maillard Marc P, Burnier Michel
Service of Nephrology and Hypertension, Department of Medicine, University Hospital, Rue du Bugnon 17, Lausanne, Switzerland.
Vasc Health Risk Manag. 2008;4(6):1159-66. doi: 10.2147/vhrm.s3510.
Despite the development of many effective antihypertensive drugs, target blood pressures are reached in only a minority of patients in clinical practice. Poor adherence to drug therapy and the occurrence of side effects are among the main reasons commonly reported by patients and physicians to explain the poor results of actual antihypertensive therapies. The development of new effective antihypertensive agents with an improved tolerability profile might help to partly overcome these problems. Lercanidipine is an effective dihydropyridine calcium channel blocker of the third generation characterized by a long half-life and its lipophylicity. In contrast to first-generation dihydropyridines, lercanidipine does not induce reflex tachycardia and induces peripheral edema with a lower incidence. Recent data suggest that in addition to lowering blood pressure, lercanidipine might have some renal protective properties. In this review we shall discuss the problems of drug adherence in the management of hypertension with a special emphasis on lercanidipine.
尽管已经研发出了许多有效的抗高血压药物，但在临床实践中，只有少数患者能达到目标血压。患者和医生普遍报告称，药物治疗依从性差和副作用的出现是实际抗高血压治疗效果不佳的主要原因。研发耐受性更好的新型有效抗高血压药物可能有助于部分克服这些问题。乐卡地平是一种有效的第三代二氢吡啶类钙通道阻滞剂，具有半衰期长和亲脂性的特点。与第一代二氢吡啶类药物不同，乐卡地平不会诱发反射性心动过速，诱发外周水肿的发生率也较低。最近的数据表明，除了降低血压外，乐卡地平可能还具有一些肾脏保护特性。在这篇综述中，我们将讨论高血压管理中药物依从性的问题，并特别强调乐卡地平。
